Company: MIRA
Filing Date: 2025-06-17
Form Type: PREM14A
Source: 0001641172-25-015340
Chunk: 24

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-17
Form: PREM14A
Chunk 24
---
 problems relating to the ability to generate sufficient cash flow to operate SKNY’s business, and additional costs and expenses that may exceed current estimates. SKNY expects to continue to incur significant losses into the foreseeable future. SKNY recognizes that if the effectiveness of its business plan is not forthcoming, it will not be able to continue business operations. There is no history upon which to base any assumption as to the likelihood that SKNY will prove successful, and it is doubtful that SKNY will generate any operating revenues or ever achieve profitable operations. If SKNY is unsuccessful in addressing these risks, SKNY’s business will most likely fail.

SKNY is an early development-stage company with no revenues.

As a very early development-stage enterprise that is focused on the development of a pre-clinical pharmaceutical product, SKNY has generated no revenue to date. There can be no assurance that SKNY will be successful in obtaining sufficient funding on terms acceptable to it to fund continuing operations, if at all, identify and enter into any strategic transactions that will provide the capital that SKNY will require or achieve the other strategies to alleviate the conditions that raise substantial doubt about SKNY’s ability to continue as a going concern. The failure to obtain sufficient capital on acceptable terms when needed may require SKNY to delay, limit, or eliminate the development of business opportunities and SKNY’s ability to achieve its business objectives. Any of such failures will materially adversely affect SKNY’s competitiveness, and SKNY’s business, financial condition, and results of operations. In addition, the perception that SKNY may not be able to continue as a going concern may cause others to choose not to deal with it due to concerns about SKNY’s ability to meet SKNY’s contractual obligations.

SKNY has significant and increasing liquidity needs and will require additional funding.

Research and development, general and administrative expenses and cash used for operations will continue to be significant and may increase substantially in the future in connection with new research and development initiatives and continued product commercialization efforts. Following the Merger, the combined company may need to raise additional capital to fund its operations, continue clinical trials to support potential regulatory approval of marketing applications and to fund commercialization of its products.

Operating results may vary significantly in future periods.

Following the Merger, the combine company’s operating and financial results are likely to fluctuate significantly in the future. SKNY’s operating and financial results are unpredictable and may fluctuate, for among other reasons, due to:

| ● | SKNY’s                                                                      
 achievement of product development objectives and milestones                |